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1. SUMMARY 
Phosphorothioate oligonucleotides have been deeply studied as antisense therapy drugs. 
Their stereoselective synthesis, however, still depends on the use of chiral auxiliaries or 
modifications on the individual nucleosides, which slow their synthesis and increase costs. A 
catalytic asymmetric synthesis of these oligonucleotides would therefore be of great interest. 
Herein the catalytic asymmetric synthesis of dinucleoside phosphorothioates is attempted. 
After failing to optimise the conditions for the coupling using 4-DMAP-N-oxides as nucleophilic 
catalysts, hydrogen bond donors were envisaged as potential catalysts. 
Through the use of bifunctional thioureas containing a tethered amine, adequate conditions 
for the coupling were found and diastereoselectivity could be measured. Although low 
conversions were obtained, moderate selectivities were achieved for the synthesis of these 
dinucleosides.  
 
 
Keywords: dinucleoside phosphorothioates, asymmetric catalysis, bifunctional thioureas, 
antisense therapy. 
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2. RESUM 
Els oligonucleòtids fosforotioats han estat intensament estudiats com a medicaments en 
teràpia antisense. Tanmateix, la seva síntesi estereoselectiva depèn encara de l’ús d’auxiliars 
quirals o modificacions en els nucleòsids, que alenteixen la síntesi i n’incrementen els costos. 
La síntesi asimètrica catalítica d’aquests oligonucleòtids desperta doncs un gran interès.  
Al present estudi s’assaja la síntesi asimètrica catalítica de dinucleòsids fosforotioats. 
Després de l’optimització fallida de les condicions de la reacció quan s’empraren 4-DMAP-N-
òxids com a catalitzadors nucleofílics, els donadors de ponts d’hidrogen van ser avaluats com a 
potencials catalitzadors. 
A través de l’ús de tiourees bifuncionals amb un grup amina, es van aconseguir condicions 
adequades per a la reacció i la diastereoselectivitat es va poder mesurar. Malgrat que les 
conversions obtingudes van ser baixes, es van obtenir selectivitats moderades en la síntesi 
d’aquests dinucleòtids. 
 
 
Paraules clau: dinucleòsids fosforotioats, catàlisi asimètrica, tiourees bifuncionals, teràpia 
antisense. 
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3. INTRODUCTION 
3.1. ANTISENSE THERAPY. THE CONCEPT 
According to the so-called central dogma of molecular biology, first stated by Crick in 1958, 
genetic information is found in DNA, and it is expressed through its transcription into mRNA, 
before being translated into proteins.1 
In the “classic” target-based drug discovery approach, molecules are screened in 
biochemical assays in order to find “hits”, which are compounds that bind to a specific protein 
known to have an important role in the metabolic route of a disease. These proteins are mainly 
ion channels, receptors or enzymes. This approach is therefore mainly focused on the 
interaction of the drug with the last product in the genetic information flow: proteins.  
However, Zamecnik and Stephenson proposed an alternative approach in 1978.2,3 They 
proved that a single, relatively short strand of unmodified DNA was capable of inhibiting the 
translation of proteins in the Rous sarcoma virus. Instead of inhibiting the activity of certain 
proteins, it was possible to avoid their synthesis through the interaction of a single strand 
oligonucleotide (ON) with their corresponding mRNA. This approach was later coined antisense 
therapy. 
Zamecnik and Stephenson’s discovery was hailed as a therapeutic approach with almost no 
limitations.4 Via Watson-Crick base pairing, specific interactions would be easily designed, and 
diseases with genetic targets or factors could be tackled. However, reality did not meet the 
expectations, mainly due to the unexpected obstacles encountered during its development. The 
most important drawbacks in antisense therapeutics development were (i) poor stability against 
nucleases, (ii) inefficient intracellular delivery, (iii) low affinity toward the target and (iv) potential 
off-target toxicity.5 As such only two antisense oligonucleotides have achieved approval by the 
FDA: fomivirsen (Vitravene, 1998, discontinued due to low demand) and mipomersen 
(Kynamro, 2013).6 
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However, the field appears to have now matured with more than 130 clinical trials listed and 
around 20 antisense drugs in phase II or III in clinical trials.6,7 It is clear then that oligonucleotide 
therapeutics have gained new momentum and will surely provide new drugs in the near future. 
 
3.2. THE MECHANISM OF ACTION OF ANTISENSE ONS 
Despite the simplicity of the concept behind antisense therapy, no simple mechanisms have 
been proposed to explain the gene expression disruption caused by ONs. Two major 
mechanisms are suspected of regulating gene expression: steric blockage and RNase H-
induced strand scission (Scheme 1).7  
 
 
Scheme 1. Mechanism of action of antisense ONs. Adapted from Future Med. Chem. 2011, 3 (3), 339–365 
 
Steric blockage is likely to be involved when modified ONs are poor activators of RNase H. 
Drug occupation of the target RNA hinders the factors involved in translation, blocking the 
binding of the ribosome to the mRNA. This generates a translational arrest of the target 
sequence. An alternative form of steric blockage takes place when the drug binds to pre-mRNA, 
which is an immature mRNA that requires further processing, called splicing. This also blocks its 
translation.  
Alternatively, modified ONs coupling to specific sequences of mRNA can lead to RNase H-
induced strand scission.8 RNase H is a ribonuclease that binds to certain DNA-RNA complexes, 
degrading only the RNA strand. This is therefore the preferred mechanism, since after 
degradation of the mRNA the modified ON is released, closing a formal catalytic cycle. 
However, it should be noted that both mechanisms contribute in variable proportions to the 
expression of the pharmacological effects of antisense therapy.7 
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3.3. CHEMICAL ASPECTS OF ANTISENSE ONS 
In order to overcome the aforementioned limitations of antisense ONs (see section 3.1), 
numerous modifications to nucleic bases, ribose or deoxyribose, as well as within the phosphate 
linkage have been explored. However, the most common and successful have been 
modifications in the backbone structure of ONs. Some of these are the replacement of one of 
the non-bridging oxygen atoms with a sulfur atom (PS-ONs), a selenium atom (PSe-ONs), a 
methyl (PMe-ONs) or a borane group (PBH3-ONs) (Figure 1).9 
 
 
Figure 1. Most common backbone modifications in ONs 
 
Nonetheless, the introduction of the phosphorothioate moiety by Eckstein in 196710 has 
been arguably the most important contribution to the field of antisense therapy. Substitution of 
the O-atom by an isoelectronic S-atom causes an increase in hydrophobicity and acidity, as well 
as geometric changes due to the more sterically demanding sulfur atom.  
Further to these properties, PS-ONs are soluble in water, interact readily with wild-type 
nucleic acids and maintain the anionic character of oligonucleotides.7,11 This modification has 
been proven to increase their nuclease resistance, but also to extend circulation times due to 
their unspecific binding to serum proteins.12,13 Moreover, in 2007, Wang and co-workers made 
an unforeseen discovery: they found a segment of bacterial DNA that contained 
phosphorothioate linkages.14 As such, PS-ONs could no longer be called ‘unnatural’ or 
‘synthetic’, since such molecular architecture is present in Nature. 
Despite the great improvement in pharmacokinetic properties afforded with PS-ONs, this 
backbone modification also implies the creation of new P-chiral centres. ONs with n nucleoside 
units include n-1 P-chiral centres, thus they exist as a mixture of 2n-1 diastereoisomers. This 
polydiastereoisomerism entails that the measured activity of these compounds is a distribution 
weighted average of the activities of all isomers, which have similar but different properties. This 
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is the reason why efforts during the last decades have been focused on the synthesis of 
oligonucleotides with stereochemically defined internucleotide linkages.9 
Several approaches have been explored throughout the years in order to obtain enantiopure 
PS-ONs: separation of diastereoisomers by column chromatography15 and the use of P-
diastereopure phosphorylating reagents.16–21 A recent publication by Davies22 reported the first 
catalytic stereoselective method for the installation of phosphorus-stereogenic 
phosphoramidates to nucleosides through a dynamic stereoselective process. The catalytic 
diastereoselective synthesis of dinucleoside phosphorothioate, however, has not yet been 
reported. Therefore, the final aim of this project can be summarised as such: the catalytic 
diastereoselective coupling of nucleosides to yield PS-ONs.  
 
3.4. PREVIOUS WORK. DMAP-N-OXIDE CATALYSIS 
Several chiral DMAP-N-oxides have been developed in Spivey group in order to catalyse 
acylation,23–25 sulfonylation,25,26 silylation25 and phosphorylation reactions27,28 (Scheme 2). 
These catalysts have also been employed in the kinetic resolution of indolines26 and sec-
alcohols.24 
 
 
Scheme 2. Applications of 4-DMAP-N-oxide catalysts developed by Spivey et. al.26,28 
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Asymmetric phosphorylation has not yet been reported by the group, but 4-DMAP-N-oxides 
have been used as organocatalysts in the site-selective phosphorylation of polyols and amino 
acid derivatives, with excellent results.28 
Fessner had previously worked on the asymmetric synthesis of phosphorothioate-
nucleosides,29 following the work by Okruszek30 in order to prepare the phosphorylating reagent. 
However, diastereoselectivity was not evaluated for the coupling reaction in the presence of 
catalyst 3.29 
Drawing analogies with previous reports from the group, 4-DMAP-N-oxide catalysts are 
potential catalysts for the coupling between a nucleoside and a phosphorothionucleoside. 
Therefore, atropisomeric 4-DMAP-N-oxide catalyst 3 previously designed by Spivey and co-
workers will be the starting point for the development of a stereoselective coupling reaction. 
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4. OBJECTIVES 
The final aim of this project is to catalyse diastereoselective coupling of a nucleoside and a 
phosphorothionucleoside to form a dinucleoside phosphorothioate (Scheme 3). An 
atropisomeric 4-DMAP-N-oxide catalyst previously reported by the group was selected as a 
potential catalyst for the reaction. Hence, the initial objectives of the project are: 
- Synthesis of the atropisomeric 4-DMAP-N-oxide catalyst 3 
- Synthesis of the phosphorylating reagent  
- Optimisation of the conditions of the coupling between the phosphorylating reagent and 
a protected nucleoside.  
- Evaluation of the diastereoselectivity of the catalysed coupling reaction 
 
 
Scheme 3. Nucleoside coupling reaction to yield a dinucleoside phosphorothioate 
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5. RESULTS AND DISCUSSION 
5.1. SYNTHESIS OF THE ATROPISOMERIC 4-DMAP-N-OXIDE CATALYST 3 
Atropisomeric 4-DMAP-N-oxide 3 was envisioned to be a potential catalyst for the 
diastereoselective coupling to yield a dinucleoside phosphorothioate (vide supra). This 
presumed reactivity was due to previous success for similar reactions in the group.23,24,26–28   
Therefore, the first aim of this project was to prepare the atropisomeric 4-DMAP-N-oxide 
catalyst 3 as a racemate, in order to later resolve it through preparative chiral HPLC. Its 
synthesis consisted of 5 steps (Scheme 4): 
 
 
Scheme 4. Synthesis of the atropisomeric 4-DMAP-N-oxide catalyst 3 
 
In the first step, pyridine 7 was coupled to 2,4-bis(trifluoromethyl)phenylboronic acid via a 
Suzuki-Miyaura coupling reaction with excellent yields and regioselectivity. The reaction takes 
place mainly in C2 due to the weaker C–Cl bond, which decreases the transition state energy of 
the rate-determining step, the oxidative addition (Scheme 5).31 
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Scheme 5. Mechanism of the Suzuki-Miyaura coupling and transition state energy diagram  
(adapted from Chem. Soc. Rev. , 2007, 36, 1036–1045) 
 
The following step was a palladium-catalysed directed C–H bromination using N-
bromosuccinimide (NBS) as both a brominating reagent and an oxidant, which yielded the 
product in also good yields (77% average). The regioselectivity of the reaction is due to the 
directing effect of the nitrogen in the pyridine ring, which binds to the Pd centre to form a 
palladacycle (Figure 2).32 The σ-arylpalladium bond in this complex is reactive and undergoes 
bromination with NBS. 
 
 
Figure 2. Reactive palladacycle in the bromination of compound 8 
 
The third step involved the oxidation of pyridine 9 with m-CPBA to form a pyridine-N-oxide. 
1H NMR showed full conversion of the starting material, and good isolated product yields were 
achieved (75 %).  
Next, the dimethylamino group was installed at the 4 position of the pyridine-N-oxide ring 
through a nucleophilic aromatic substitution. The reaction was carried out under microwave 
irradiation, in order to increase the rate of the reaction but also to ensure its regioselectivity. 
Under microwave activation, if the polarity of a system is enhanced from the ground state to the 
transition state, such a change results in an acceleration of that particular reaction path.33 
Therefore, substitution of the chloride is the preferred pathway, since the polarity of the C–Cl 
bond contributes more strongly towards the overall molecular dipole. 
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The following step was a Suzuki-Miyaura coupling between compound 11 and meta-
terphenyl boronic acid. This boronic acid is commercially available and had been sourced for 
previous preparations of the catalyst. However, this time a route to prepare meta-terphenyl 
boronic acid was explored to reduce costs in the synthesis of the catalyst. 
Following a literature search, a protocol towards the synthesis of boronic acid 15 was found 
and summarized in scheme 6.34 
 
 
Scheme 6. Synthesis of meta-terphenylboronic acid by Kang et. al.34  
 
In the first step, a double Suzuki-Miyaura coupling between phenylboronic acid and 
chlorobenzene 13 was carried out. After 5 hours, no starting material could be detected either 
by TLC or 1H NMR. However, the purification of compound 14 was challenging, since two side-
products with very similar polarities to the product were formed (Scheme 7). Both side-products 
were identified through 1H NMR and MS: compound 16 was the monocoupling product, and 
compound 17 the reduction product.  
 
 
Scheme 7. Product and side-products of the Suzuki-Miyaura coupling 
 
The following reaction was a Miyaura coupling between compound 14 and 
bispinacolatodiboron using SPhos as a ligand. SPhos is a ligand designed by Buchwald et. al. 
to increase reactivity of the palladium complex and enable the coupling of hindered substrates.35 
The premixing of the ligand and the palladium precatalyst was found essential for the reduction 
of reaction times (from eight to five hours),34 as well as a concomitant increase in the isolated 
yield of product (98% vs 67% reported by Kang).34 Compound 12 was purified by a very fast 
chromatography column, since it is prone to hydrolysis on silica.  
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Finally, the hydrolysis of boronic ester 12 was carried out using sodium periodate and 
hydrochloric acid to give boronic acid 15 in quantitative yield with no need for further purification. 
Pinacol, the alcohol released during hydrolysis, undergoes oxidative cleavage with sodium 
periodate to produce acetone.  
Therefore, and after three steps, meta-terphenyl boronic acid 15 was obtained with a 49% 
overall yield. 
Once boronic acid 15 was available, the last step of the synthesis of the catalyst 3 could be 
carried out. However, this reaction had been reported to be a challenging step, since no yields 
higher than 50% had been reported in the group.26,29 
As the synthesis of boronic acid 15 went via boronic ester 12, a comparison of the 
performance of the ester and acid was conducted in an attempt to shorten the overall synthesis. 
The ligand and palladium adduct were premixed, and after 8 hours (instead of the reported 72 
hours26) no starting material could be detected in the reaction containing the boronic ester. After 
isolation, yields could be compared and, unexpectedly, boronic ester 12 performed better with 
no need for optimisation of the conditions (Table 1). 
 
 
Entry X Isolated yield 3 (%) 
1 B(OH)2 50 
2 Bpin 79 
 
Table 1. Comparison of the performance of boronic ester 12 and boronic acid 13 in the coupling reaction. 
 
Thanks to this increase in yield, catalyst 3 was synthesized in 5 steps with 43% overall yield. 
 
 5.2. SYNTHESIS OF THE PHOSPHORYLATING REAGENT 
In order to prepare dinucleoside phosphorothioates a phosphorylating reagent is needed. 
This reagent has to contain a prochiral phosphorus, as well as some moiety that will yield the 
negatively charged sulphur atom. Following Okruszek’s work, compound 23 was chosen to be 
the object of the nucleophilic attack,30 and it was prepared according to their protocol 
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(Scheme 8). The deoxynucleoside of choice for the synthesis of the phosphorylating reagent 
was thymidine, since it has no functionalities to be protected.  
 
 
Scheme 8. Synthesis of phosphorylating reagent 23 by Okruszek30 
 
Okruszek described the synthesis of dithiaphospholane 20 from phosphorus trichloride, 
diisopropylamine and 1,2-ethanedithiol (Scheme 8).30 However, the described procedure 
involved distillation of phosphorodichloridite 19, which is pyrophoric and explosive when dry. For 
safety reasons, the protocol was modified in order to maintain compound 19 in solution.  
Following this modified procedure (see section 6.3) dithiaphospholane 20 was prepared with 
good yields (64%) with no further purification. Both steps were simple substitutions on the 
phosphorus trichloride starting material, producing insoluble salts (diisopropylammonium 
chloride and triethylammonium chloride) that were filtered to yield a relatively pure solution of 
the product. Due to its intrinsic instability, compound 20 was stored under argon in a sealed vial, 
and its purity monitored periodically by 31P NMR.  
For the coupling between nucleoside 21 and dithiaphospholane 20, a one-pot synthesis was 
explored, since it was hypothesised that P(III) compound 22 would be relatively unstable and 
prone to hydrolysis. Hence, by avoiding purification of compound 22, higher yields would be 
obtained. Unfortunately, even though the coupling reaction proceeded smoothly, the oxidation of 
P(III) compound 22 to yield phosphorylating reagent 23 was not successful. The proposed 
explanation being that the presence of tetrazole in solution may distort the oxidation reaction, 
since a complex 31P NMR spectrum was obtained in all attempts. 
Once the one-pot synthesis was discarded, the procedure for the coupling and oxidation as 
described by Okruszek30 was followed with no major modifications. Nucleoside 21 was coupled 
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to dithiaphospholane 20 using tetrazole as a nucleophilic catalyst with excellent yields (86% 
average). This was a major improvement on the results previously reported, since conversions 
had always been reported lower than 50%.29 A plausible reason for this may be differences in 
the purity of compound 20. Despite the fact of being a P(III) compound, nucleoside 22 was 
purified by column chromatography without apparent loss of product due to decomposition.  
Finally, compound 22 was oxidized through the addition of tert-butyl hydroperoxide. After 
1 hour at room temperature no starting material could be detected by 31P NMR or TLC, and 
through the addition of anhydrous hexane the product was obtained as a white precipitate. In 
contrast to P(III) compound 22, which was relatively stable in silica, P(V) compound 23 
hydrolysed rapidly on the TLC plate. Fortunately, centrifugation of the suspension was enough 
to obtain pure phosphorylating reagent 23, since the main side-product of the reaction was tert-
butanol, which stayed in solution. 
During characterization of compound 23, a second peak in the 31P NMR was always present 
in variable proportions (31P NMR:  82.7, 81.7 ppm, CDCl3). Since its intensity increased from 
the moment the sample was prepared, it was thought to be the product of hydrolysis – even 
though a markedly upfield shift would be expected for a phosphorothioic acid.  
In order to confirm or reject this hypothesis, a simple 31P NMR experiment was carried out. 
The phosphorylating reagent 23 was mixed in a NMR tube with deuterium oxide and DBU as a 
non-nucleophilic base. After 15 minutes, no starting material could be detected by 31P NMR, and 
two new peaks appeared at  15.8 and 16.1 ppm. These corresponded to both diastereomers of 
the hydrolysis product 24, which exist as DBU salts (Scheme 9). 
 
 
Scheme 9. DBU-catalysed hydrolysis of phosphorylating reagent 23. 
 
This experiment proved that the second peak at 81–83 ppm was not the hydrolysed 
starting material, but did not help towards its identification. After conducting a literature search, 
a reasonable explanation was found: nucleosides like thymidine have two main conformers (syn 
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and anti) depending on the relative position of the nucleic base and the deoxyribose 
(Scheme 10). 
 
  
Scheme 10. Conformational equilibrium of thymidine in solution36–38 
 
These conformations have been deeply studied,36–39 and it is known that their relative 
populations depend on the solvent and their state, crystalline or in solution. In a solid form, 
thymidine exists as an individual high energy conformer, the anti. However, when the substance 
is in solution both conformers tend to equilibrate towards ratios that vary from 8:5 to 3:5 
depending on the temperature.37 Despite the difference in structure between the 
phosphorylating reagent and thymidine, these conformations are compatible with both and 
hence this is the proposed explanation for the appearance of the second peak in the 80 ppm 
region. 
 
5.3. MODEL REACTION: COUPLING BETWEEN PHOSPHORYLATING REAGENT 23 AND 
BENZYL ALCOHOL  
5.3.1 Screening of bases 
Before facing the formation of dinucleoside phosphorothioates, the coupling between 
compound 23 and benzyl alcohol was studied as a model reaction. Benzyl alcohol was chosen 
since it is UV active, a primary alcohol and analysis of the reaction outcome would be relatively 
simple. 
In order to achieve high levels of diastereoselectivity the difference in rate of the catalysed 
and non-catalysed reaction is crucial. Therefore, at this stage of the project, reaction conditions 
were optimised to achieve this difference of reactivity. 
Since DBU is known to catalyse the reaction between compound 23 and a second 
nucleoside30 –and keeping in mind the necessity to minimise the non-catalysed reaction– a 
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screening of milder bases was carried out (Table 2). Propylene oxide (PPO) appeared an ideal 
candidate for the catalysed coupling, since no reaction took place in its presence (Table 2, 
entry 2). Moreover, Spivey et. al. have reported its use as a proton scavenger for the catalysed 
phosphorylation of alcohols.28 Triethylamine, 1,2,2,6,6-pentamethylpiperidine (PMP) and 
2,2,6,6-tetramethylpiperidine (TMP) showed conversions to the desired product between 25 and 
60%, while the reaction in the presence of DBU went almost to completion in agreement with 
the results reported by Okruszek.30 
 
 
Entry Base Conv. (%)a 
1 DBU 90 
2 PPO nr 
3 NEt3 55 
4 PMP 25 
5 TMP 60 
6 - nr 
7b PPO nr 
(a) Conversion to the desired product, determined by 31P NMR; (b) 
Reaction carried out in the presence of 25 mol% catalyst 3 
Table 2. Impact of the base on the reaction conversion 
 
Taking this into account, and following the work by Spivey28, a reaction was set using PPO 
as a proton scavenger and 4-DMAP-N-oxide catalyst 3. Propylene oxide would enable the 
reaction to occur without promoting background reaction. Unfortunately, no reaction was 
detected (Table 2, entry 7). 
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Scheme 11. Proposed mechanism for the 4-DMAP-N-oxide catalysis 
 
The absence of reactivity could have two main reasons: (a) lack of nucleophilic attack of the 
DMAP-N-oxide on the phosphorus centre or (b) absence of the subsequent attack of the alcohol 
(Scheme 11). 
The presence of the catalyst had been proven to be necessary for the hydrolysis of 
compound 23 to occur. Therefore, hypothesis (a) was discarded, since almost quantitative 
catalysed hydrolysis of compound 23 implied turnover of the catalytic cycle.  
 
5.3.2 Basic activation of the nucleophile 
Phosphorylating reagent 23 was not as reactive as expected towards a nucleophilic attack. 
Therefore, efforts were now focused on the screening of conditions or additives that could 
activate either the nucleophile or electrophile, enhancing the reactivity of the system. The 
achiral catalyst 6 was used during the optimisation process as a model catalyst. 
The first approach, taking into the account results in table 2, was to use a base in order to 
increase the nucleophilicity of benzyl alcohol. A very mild base at low temperature would be a 
good candidate, since it would increase the reactivity of the system while attenuating the 
background reaction. A number of reactions were set, in order to explore the potential of this 
approach (Table 3). Unfortunately, at low temperatures no reaction could be achieved with PMP 
or Cs2CO3, and at higher temperatures the differential rate of the background reaction 
compared to catalysed reaction would be unsatisfactory (Table 3, entry 5). 
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Entry Base (1 equiv.) Catalyst (20 mol%) Conv. (%)a 
1 PMP - nr 
2 PMP 6 nr 
3 Cs2CO3 - nr 
4 Cs2CO3 6 nr 
5b PMP - 25 
(a) Determined by 31P NMR; (b) Reaction carried out 30 min at room temperature  
Table 3. Basic activation of the reaction 
 
5.3.3 Lewis acid activation of the electrophile 
A second approach was the activation of the phosphorylating reagent through the decrease 
of electron density on the phosphorus. The most common method to do this is the addition of a 
Lewis acid as an additive. The coordination of a Lewis acid to the phosphorylating reagent was 
expected to increase the electrophilicity of the phosphorus making it more reactive towards the 
alcohol/alkoxide. This strategy was supported also by the fact that Sculimbrene and coworkers 
have reported the Lewis acid catalysed phosphorylation of alcohols.40 
In Sculimbrene’s work, different Lewis acids were screened in order to catalyse the 
phosphorylation of a secondary alcohol by a diphosphate. Titanium and scandium salts were 
reported as catalysts for this reaction, so they were both included in our screening towards an 
adequate additive (Table 4, entries 5-8). Unfortunately, in the presence of boron trichloride 
diethyl ethereate or scandium triflate no conversion could be detected with or without catalyst 6. 
On the contrary, titanium tetraisopropoxide promoted the reaction in both the catalysed and 
non-catalysed route, which would be incompatible with high levels of diastereoselectivity. 
Therefore, milder conditions for the activation of the substrate needed to be explored. 
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Entry Catalyst (20 mol%) Additive (20 mol%) Conv. 2h (%)a Conv. 3h (%)a 
1 - - nr  nr 
2 6  - nr nr  
3 - BCl3·Et2O nr nr  
4 6  BCl3·Et2O nr nr  
5 - Ti(OiPr)4 nr 50 
6 6 Ti(OiPr)4 nr  80 
7 - Sc(OTf)3 nr  nr  
8 6 Sc(OTf)3 nr  nr  
(a) Determined by 31P NMR 
Table 4. Additives effect on the coupling reaction 
 
5.3.4 Hydrogen bond donor cocatalysis 
Since the results after using mild bases or Lewis acids were not promising, a completely 
different approach was proposed: using a hydrogen bond donor as a cocatalyst in the reaction. 
Hydrogen bond donors, particularly ureas and thioureas, have been deeply studied as 
organocatalysts.41–45 They have been shown to activate a broad scope of substrates, including 
carbonyls,46–52 phosphates53 and imines54,55 and a large number of chiral analogues of the 
thiourea scaffold have been designed with great success.43,45 Moreover, Seidel et. al. reported 
the use of these chiral thioureas in combination with 4-DMAP to catalyse enantioselective acyl 
transfer reactions, that have enabled the kinetic resolution of several amines,56,57 including 1,2-
diaryl-1,2-diaminoethanes,58 meso-diamines,59 propargylic60 and allylic amines.61 
Thus, phosphorylating reagent 23 was envisaged to be a 
good substrate for this kind of activation, since hydrogen 
bonding should decrease electron density on the phosphorus 
and therefore increase its electrophilicity (Figure 3). 
Schreiner’s thiourea catalyst 30 was the additive of choice, 
since it has been demonstrated to be especially active in a 
variety of transformations.53,62 
 
Figure 3. Proposed hydrogen bond 
donation of thiourea 30 to the 
substrate 
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A new set of reactions were carried out in order to determine whether thioureas were 
adequate additives for the coupling (Table 5). The results obtained were promising: Schreiner’s 
thiourea appeared to be activating the phosphorylating reagent through hydrogen bond 
donation. However, in the absence of 4-DMAP-N-oxide the reaction also proceeded due to this 
activation even at very low catalyst loadings of Schreiner’s catalyst (Table 5, entries 3-4). Thus, 
the use of an achiral thiourea as a cocatalyst was discarded, due to the unsatisfactory ratio 
between the catalysed and non-catalysed reaction. However, these same experiments 
supported a different approach: the use of a chiral thiourea alone as an organocatalyst for the 
reaction. 
 
 
Entry Catalyst (20 mol%) Additive (20 mol%) Conv. 2h (%)a Conv. 3h (%)a 
1 - 30 30 na 
2 6 30 80 na 
3 - 30b nr  40 
4 6 30b nr  90 
(a) Determined by 31P NMR; (b) 1 mol%. 
Table 5. Effect of the addition of Schreiner's thiourea 30 to the reaction 
 
Schreiner’s thiourea catalyst, without any complementary additive, enabled the coupling to 
take place. Moreover, it had been also proven that in its absence no conversion could be 
detected (Table 4, entry 1). Therefore, chiral thioureas were finally defined as the potential 
catalysts for the studied coupling. Hence, the next step would be to find an adequate chiral 
thiourea that would catalyse a diastereoselective reaction between the phosphorylating reagent 
23 and a second nucleoside.  
 
5.4. COUPLING BETWEEN PHOSPHORYLATING REAGENT 23 AND A NUCLEOSIDE 
5.4.1 Selection of the hydrogen bond donor catalyst 
Once chiral thioureas had been set as the lead catalysts, benzyl alcohol was no longer used 
in the coupling reactions. Instead, 3’-O-acetylthymidine was used as the nucleophile for the 
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coupling. Thymidine was chosen as the nucleophile, since a homodinucleoside was thought to 
be the simplest model for the reaction.  
Before facing the challenging task of finding an adequate chiral thiourea for the reaction, a 
set of experiments were carried out with the achiral thiourea 30, in order to gain an insight into 
the reactivity of the phosphorylating reagent 23 with protected thymidine 39.a (Scheme 12).  
 
 
Scheme 12. Coupling between phosphorylating reagent 23 and nucleoside 39.a 
 
Surprisingly, no reaction could be detected for any of the conditions tested (see appendix, 
entries 4-9) despite the fact that benzyl alcohol had been reactive as a nucleophile under some 
of these conditions (Table 5). The protected nucleoside appeared to be a much less reactive 
nucleophile than benzyl alcohol, which had been used as a model. This difference in reactivity 
may well be due to the existence of an intramolecular hydrogen bond between the reacting 
hydroxyl group and a hydrogen of the heterocycle,63 which increases its steric hindrance 
(Figure 4). 
 
 
Figure 4. Lowest energy conformer of thymidine. Adapted from J. Phys. Chem. B 2007, 111, 9655-9663 
 
One simple way to increase the nucleophilicity of the second nucleoside would be to 
increase the number of equivalents of base, or even to increase the concentration of all 
reactants. However, both these methods were proven to cause the appearance of undesired 
background reaction by general base catalysis (see appendix, entries 14, 16, 18). 
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A second approach was proposed and applied: through the addition of a tethered amine to 
the catalyst, the local concentration of base would increase notably, while keeping the rate of 
the background reaction low. Therefore, a literature search was conducted in order to find a 
thiourea catalyst with a base present within the scaffold (Figure 5). 
 
 
Figure 5. Some popular chiral thiourea organocatalysts49,64–68 
 
Further to this, the ideal structure would have: (i) chirality near to the thiourea moiety; (ii) 
presence of a tethered amine; (iii) electron deficient ring bound to the thiourea moiety, which 
increases its hydrogen bond donation62 and (iv) tuneable structure. Following these criteria, 
Takemoto catalyst was chosen to be the most suitable candidate for the asymmetric synthesis 
of dinucleoside phosphorothioates.  
 
5.4.2 Synthesis of Takemoto’s catalyst analogues and optimisation of the coupling 
conditions 
Berkessel reported a particularly interesting simplified synthesis of Takemoto’s catalyst that 
yields primary amine C1 as an intermediate (Scheme 13). This synthesis consisted on the 
sequential coupling of aniline 36, chlorothioformate 37 and diaminocyclohexane 38; followed by 
reductive amination with formaldehyde to provide catalyst C2. Primary amine C1, apart from 
being a potential catalyst for the coupling, is also the starting material for a broad number of 
modifications to yield a scope of catalysts readily available after one or two steps, through e.g. 
alkylation or acylation.  
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Following this stereospecific route, (±)-C1 and (±)-C2 were prepared before the optimisation 
of the conditions for the coupling. 
 
 
Scheme 13. Simplified synthesis of Takemoto's catalyst by Berkessel69 
 
Concentration, temperature and time were the key parameters for the optimisation, since 
they would determine the difference in rate of the catalysed and background reactions. After an 
initial screening (see appendix, entries 10-25), optimal conditions for the coupling were 
determined in which no conversion could be detected without any catalyst, but reaction took 
place in its presence. Unfortunately, low conversions were always obtained irrespective of the 
reaction conditions. This may be due to the fast hydrolysis of the starting material to form PMP 
salt 24 or because of the inhibition caused by the hydrogen bonding between the catalyst and 
dinucleoside 40.a or 24. In order to increase the conversion, 4Å molecular sieves were added to 
the reaction mixture yielding better but still low conversions (see appendix, entries 22-25). 
 
5.4.3 Evaluation of the diastereoselectivity of the coupling 
Once reaction conditions had been optimised, a set of homochiral catalysts were prepared 
in order to measure their chirality induction. Following Berkessel’s protocol, (R,R)-C1, (S,S)-C1 
and (R,R)-C2 were synthesised. Moreover, and in order to shed some light on the reaction 
transition state, the monoalkylated and bulkier thiourea (R,R)-C3 was also synthesized through 
reductive amination of (R,R)-C1 (Scheme 14).55  
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Scheme 14. Reductive amination of primary amine C1 to secondary amine C3. 
 
Diastereomeric ratios were measured by 31P NMR, and assignment was carried out 
following work by Okruszek and co-workers.30 The assignment was based upon analysis of the 
31P NMR chemical shifts and RP-HPLC retention times and their comparison with original 
samples prepared independently by a phosphoramidite methodology.70 Using these methods, 
they established that RP isomers of all dinucleoside phosphorothioates appear at higher 
frequencies in the 31P NMR and lower retention times in RP-HPLC. 
In order to evaluate the diastereoselectivity of the catalysed reaction, the intrinsic selectivity 
due to the chirality in the reactants had to be first measured. Because of the existence of a 
chiral environment around the reactive sites of both the electrophile and the nucleophile, natural 
selectivity needs to be measured. In order to do so, blank experiments were carried out at 
higher concentrations – known to enable the general basic catalysed reaction (see section 6.6). 
Also, to shed light on the actual role of the base in the reaction, these blank experiments were 
carried out using PMP, TMP and DBU as a base (Table 6).  
 
 
Entry Base Natural RP/SP(%)b 
1 DBU 45:55c 
2 TMP 55:45 
3 PMP 71:29 
a) Determined by 31P NMR; (b) Determined by 31P NMR, and assigned following  
Okruszek’s work30; (c) In agreement with Okruszek’s data30 
Table 6. Natural selectivities obtained in the presence of different bases 
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 Surprisingly, the natural selectivity was found to be highly base 
dependant. This confirmed the role of the base as a general base 
catalyst; however, it also raised questions as to the nature of the 
transition state. One hypothesis to explain the preference towards 
the RP isomer is that if the rotation of the C3-O bond is restricted 
through repulsion of the lone pairs of the phospholane and the 
furan oxygen, then the two possible trajectories for the nucleophilic 
attack of the incoming alcohol nucleophile would be energetically very different. Trajectory (a), 
which yields the RP isomer, would be more favoured than trajectory (b), which yields the SP 
isomer, because the latter leads the incoming nucleophile to clash with pyrimidine (Figure 6). 
This is in agreement with the results obtained with PMP, but does not explain the base 
dependence or the results obtained using DBU as a base. Computational studies and a set of 
experiments using different bases, nucleophiles and phospholanes would help in the elucidation 
of this transition state geometry. 
Once the natural selectivity had been determined, evaluation of the induced 
diastereoselectivity by the H-bonding/base dual-catalysts could be measured. Applying the 
optimised conditions (see section 6.5) and using the previously prepared chiral catalysts (R,R)-
C1, (S,S)-C1, (R,R)-C2 and (R,R)-C3, as well as the commercial Jacobsen’s thiourea catalyst 
(S)-C4, RP/SP ratios were determined by 31P NMR (Table 7). 
 
 
Figure 6. Proposed 
geometry of the transition 
state of the coupling. 
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Entry Catalyst Conv. (%)a RP/SP (%)b 
1 (R,R)-C1 29 79:21 
2 (S,S)-C1 27 59:41 
3 (R,R)-C2 14 72:28 
4 (R,R)-C3 12 61:39 
5 (S)-C4 39 70:30 
(a) Determined by 31P NMR; (b) Determined by 31P NMR, and assigned following  
Okruszek’s work30  
Table 7. Evaluation of induced selectivities using different thiourea catalysts   
 
The results obtained proved that chiral thioureas that contain a tethered amine are potential 
catalysts for the synthesis of dinucleoside phosphorothioates. Even though high levels of 
diastereoselectivity proved elusive, these catalysts do affect the ratios of diastereomers formed 
and so must be influencing the energies of the preceding diastereomeric transition states. 
The highest selectivity was obtained in the presence of catalyst (R,R)-C1, which contains a 
primary amine as a tethered base. However, there was no obvious relationship between the 
results obtained with catalysts (R,R)-C2 and (R,R)-C3, which contain a tertiary and a secondary 
amine, respectively. No link was found between the basicity or bulkiness of the base and the 
measured selectivity. It is possible that more subtle effects may be responsible for this non-
intuitive behaviour; so Sigman analysis71,72 would likely be informative for optimisation of the 
catalyst.  
Finally, and in order to further understand the effect of the structure of the nucleosides in the 
coupling, natural and induced selectivity were also evaluated for the coupling of the 
phosphorylating reagent with deoxyadenosine and deoxycytidine using (R,R)-C1 as a catalyst 
(Table 8). 
 
Entry B Z Conv. (%)a RP/SP (%)b,c Natural RP/SP (%)b,d 
1 dAde - nr na 63:37 
2 dCyt N4-acetyl 14 59:41 77:23 
(a) Determined by 31P NMR; (b) Determined by 31P NMR, and assigned following Okruszek’s work30; 
(c) Following procedure in section 6.5; (d) Following procedure in section 6.6 
Table 8. Evaluation of natural and induced selectivities with different nucleosides 
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The results obtained for the natural selectivity of the coupling 
of phosphorylating reagent 23 and protected nucleosides 39.b-c 
were similar to the ones obtained for the coupling with thymidine 
39.a. For the catalysed reaction, however, adenosine 39.b did not 
yield the desired product but the product of N-nucleophillic attack 
to the phosphorylating reagent 41 (Figure 7). This was due to 
inadequate protection of the amino group at the 6 position the 
adenine ring. Interestingly, (R,R)-C1 which increased selectivity 
towards the Rp isomer in the coupling with 39.a (natural: 71:29; 
measured: 79:21), did the opposite when deoxycytidine 39.c was used as a nucleophile 
(natural: 77:23; measured: 59:41)(Table 8). 
In summary, bifunctional thioureas which bear an amine group are potential catalysts for the 
asymmetric synthesis of dinucleoside phosphorothioates; however, the catalysts evaluated 
herein provided low conversions and low to moderate selectivities. 
 
 5.5. FUTURE WORK 
Bifunctional thioureas have been proven to be potential catalysts for the asymmetric 
synthesis of nucleoside phosphorothioates. However, results obtained in this study are far from 
optimal and need to be improved. In order to do so, conversion and selectivity of the coupling 
need to be increased. 
Low conversions have been identified to be due to hydrolysis of 
the starting material, which is also catalysed by the thiourea catalyst 
and takes place simultaneously to the coupling reaction. In order to 
minimise this side-reaction, apart from thorough drying of the solvents 
and reactants, a modification to the phosphorylating reagent may be 
useful. Modification of the 5-membered ring dithiaphospholane to a less strained six-membered 
ring (Figure 8) may reduce the instability of the phosphorylating reagent towards hydrolysis. 
This, together with other modifications on the reaction conditions should be explored in order to 
achieve higher conversions and isolated yields. 
In order to achieve higher levels of diastereoselectivity, further screening of catalysts – 
including bifunctional squaramides – and conditions are needed. Moreover, elucidation of the 
 
Figure 7. N-nucleophillic 
attack product 41 
 
Figure 8. Modified 
phosphorylating reagent 
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transition state of the reaction and sources of chirality induction may be also useful, so rational 
design of the catalyst can be performed. In order to gain an insight in these, computational 
studies or Sigman analysis (vide supra) could be performed. 
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6. EXPERIMENTAL SECTION 
6.1. GENERAL DIRECTIONS 
All reactions were performed under nitrogen using oven-dried glassware unless stated 
otherwise. Yields refer to chromatographically and spectroscopically (1H-NMR) homogenous 
materials, unless otherwise indicated. CH3CN, CH2Cl2, THF, hexane and toluene were dried and 
deoxygenated with a Grubbs Pure-Solv 400 solvent purification system. All other materials were 
obtained from commercial suppliers and used without further purification unless stated 
otherwise. Flash chromatography (FC) was performed on silica gel (Merck Kieselgel 60 F254 
230-400 mesh) unless otherwise stated. Thin Layer Chromatography was performed on Merck 
aluminium-backed plates pre-coated with silica (0.2 mm, 60 F254) which were visualized either 
by quenching of ultraviolet fluorescence (λmax= 254 and 366 nm) or by charring with 10% KMnO4 
in 1 M H2SO4. Melting points were determined on a Stanford Research System OptiMelt. Optical 
rotations were measured with a Bellingham Stanley APP440+ Polarimeter. Standard infra-red 
spectra were recorded on Perkin-Elmer Two Spectrum ATR-IR spectrometer and Shimadzu 
IRAffinity-1S. Only selected absorbances are reported. 1H NMR spectra were recorded at 400 
MHz on a Bruker DRX-400 instrument. Chemical shifts (H) are quoted in parts per million 
(ppm), referenced to the residual solvent peak as an internal standard. Coupling constants (J) 
are reported to the nearest 0.1 Hz. 13C NMR spectra were recorded at 100 MHz on Bruker 
AMX- 400 instrument. Chemical shifts (C) are quoted in ppm, referenced to the residual solvent 
peak as an internal standard. High-resolution mass spectra (m/z) were recorded on Micromass 
Autospec Premier spectrometer with magnetic sector detector. High Resolution Mass 
Spectrometry (HRMS) measurements are valid to ±5ppm.  
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6.2. PREPARATION OF THE 4-DMAP-N-OXIDE CATALYST 3 
2-(2,4-Bis(trifluoromethyl)phenyl)-4-chloropyridine (8)26 
According to the method of Spivey,26 2,4-bis(trifluoromethyl)phenylboronic 
acid (2.2 g, 8.5 mmol, 1.5 equiv.), potassium phosphate (2.4 g, 11 mmol, 
2.0 equiv.) and Pd(PPh3)4 (0.39 g, 6 mol%) were dissolved in a 1:3 mixture of 
degassed water:THF (133 mL). After the addition of 2,4-dichloropyridine 
(0.84 g, 5.7 mmol, 1.0 equiv.) the mixture was heated (85 °C) for 16 h under a nitrogen 
atmosphere. The reaction mixture was then allowed to cool down to room temperature and 
40 mL of ethyl acetate were added. The organic layer was separated and washed with brine (2 
x 20 mL), dried over MgSO4 and concentrated in vacuo. The resulting oil was purified by column 
chromatography (5-15% EtOAc in hexane) and provided the product as an off-white powder 
(1.8 g, 97%). m.p. = 67.4 – 70.8 °C; Rf = 0.35 (EtOAc/hexane, 1:4); IR (neat, cm-1) 1574, 1555, 
1345, 1282, 1071;  1H NMR (400 MHz, CDCl3):  8.61 (d, J = 5.4 Hz, 1H), 8.04 (s, 1H), 7.90 
(d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 1.8 Hz, 1H), 7.39 (dd, J = 5.4, 1.8 Hz, 
1H); 13C NMR (100 MHz, CDCl3):  157.7, 150.3, 144.3, 142.2, 132.3, 131.3 (q, J = 33.7 Hz), 
129.3 (q, J = 32.2 Hz), 128.5, 124.5, 124.2, 123.8, 123.6, 121.8; HRMS (m/z +ES): Found: 
M+H, 326.0171. C13H635ClF6N+ requires M+H, 326.0179; ∆ = 2.5 ppm. Spectroscopic data in 
agreement with literature.26 
 
2-(2-Bromo-4,6-bis(trifluoromethyl)phenyl)-4-chloropyridine (9)26 
According to the method of Spivey,26 pyridine 8 (0.76 g, 2.5 mmol, 1.0 equiv.), 
N-bromosuccinimide (0.89 g, 5.0 mmol, 2 equiv.) and Pd(PPh3)4 (0.220 g, 7.5 
mol%) were dissolved in acetonitrile (17 mL) in a 20 mL microwave vial. The 
reaction mixture was then heated to 180 °C for 20 min in a microwave reactor. 
The solution was then allowed to cool down and the solvent evaporated in vacuo. The resulting 
oil was purified by column chromatography (5% EtOAc in hexane) to provide 2-(2-bromo-4,6-
bis(trifluoromethyl)phenyl)-4-chloropyridine as a yellow solid (0.78 g, 78%). m.p. = 42.0 – 
44.7 °C; Rf = 0.45 (EtOAc/hexane, 1:4); IR (neat, cm-1) 1576, 1556, 1329, 1284, 892; 1H NMR 
(400 MHz, CDCl3):  8.64 (d, J = 5.4 Hz, 1H), 8.14 (s, 1H), 7.99 (s, 1H), 7.42 (dd, J = 5.4, 
2.0 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H); 13C NMR (100 MHz, CDCl3):   156.3, 150.3, 144.4, 142.2, 
133.3, 132.5 (q, J = 34.1 Hz), 131.6 (q, J = 32.1 Hz), 126.2, 124.9, 124.0, 123.6, 122.4, 120.9; 
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HRMS (m/z +ES): Found: M+H, 403.9276. C13H679Br35ClF6N+ requires M+H, 403.9295; 
∆ = 4.7 ppm. Spectroscopic data in agreement with literature.26 
 
2-(2-Bromo-4,6-bis(trifluoromethyl)phenyl)-4-chloropyridine-N-oxide (10)26 
According to the method of Spivey,26 pyridine 9 (0.50 g, 1.2 mmol, 1.0 equiv.) 
was dissolved in CH2Cl2 (10 mL) and cooled to 0 °C in an ice bath. Then, a 
solution of NaHCO3 (0.21 g, 2.5 mmol, 2.0 equiv.) in 4.0 mL of water and m-
CPBA (<77% m/m, 0.57 g, 2.5 mmol, 2.0 equiv.) were added to the solution. 
The resulting mixture was heated to reflux (40 °C) for 16 h. The reaction was then quenched 
with 25 mL of saturated Na2SO4 solution, the phases separated and the resulting organic layer 
washed with saturated NaHCO3 solution (10 mL) and brine (20 mL) adding CH2Cl2 before every 
wash (3 x 20 mL). The resulting solution was then dried over MgSO4, concentrated in vacuo and 
purified by column chromatography (65% EtOAc in petroleum ether) providing 2-(2-bromo-4,6-
bis(trifluoromethyl)phenyl)-4-chloropyridine-N-oxide as an off-white powder (0.43 g, 83%). 
m.p. = 126.3 – 128.6 °C; Rf = 0.35 (65% EtOAc in petroleum ether); IR (neat, cm-1) 3106, 1402, 
1335, 1252, 1132; 1H NMR (400 MHz, CDCl3):  8.31 (d, J = 7.0 Hz, 1H), 8.20 (s, 1H), 8.05 
(s, 1H), 7.43 (dd, J = 7.0, 3.0 Hz, 1H), 7.30 (d, J = 3.0 Hz  1H); 13C NMR (100 MHz, CDCl3):  
 146.2, 140.5, 135.2, 133.8, 133.4, 132.7 (q, J = 32.2 Hz), 132.1 (q, J = 32.3 Hz), 130.9, 127.5, 
127.0, 123.4, 122.7, 120.8; HRMS (m/z +ES): Found: M+H, 419.9245. C13H679Br35ClF6NO+ 
requires M+H, 419.9225; ∆ = 4.8 ppm. Spectroscopic data in agreement with literature.26 
 
2-(2-Bromo-4,6-bis(trifluoromethyl)phenyl)-4-dimethylaminopyridine-N-oxide (11)26 
According to the method of Spivey,26 pyridine-N-oxide 10 (0.30 g, 0.71 mmol, 
1.0 equiv.) was dissolved in 3.0 mL of acetonitrile in a microwave vial. 
Dimethylamine (60% aqueous solution, 4.3 mL) was added and the reaction 
mixture was then heated in a microwave reactor for 30 min (100 °C). The 
resulting yellow solution was concentrated in vacuo and purified by column chromatography (2-
propanol/EtOAc, 1:1) to provide a yellow solid (0.26 g, 86 %). m.p. = 150.0 – 156.3 °C; Rf = 0.20 
(2-propanol/EtOAc, 1:1); IR (neat, cm-1) 2927, 1634, 1619, 1508, 1129; 1H NMR (400 MHz, 
CDCl3):  8.15 (d, J = 7.6 Hz, 1H), 8.13 (s, 1H), 7.98 (s, 1H), 6.63 (dd, J = 7.6, 3.5 Hz, 1H), 6.39 
(d, J = 3.5 Hz, 1H), 3.05 (s, 6H); 13C NMR (100 MHz, CDCl3):   147.4, 144.6, 139.7, 137.2, 
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133.2, 132.8 (q, J = 34.2 Hz), 132.0 (q, J = 31.9 Hz), 127.2, 123.6, 122.6, 120.8, 108.6, 39.8; 
HRMS (m/z +ES): Found: M+H, 429.0035. C15H1279BrF6N2O+ requires M+H, 429.0037; ∆ = 0.5 
ppm. Spectroscopic data in agreement with literature.26 
 
(±)-4-(Dimethylamino)-2-(5’-phenyl-3,5-bis(trifluoromethyl)-[1,1':3',1''-terphenyl]-2- 
yl)pyridine-N-oxide (3)26 
Based on the procedure of Spivey,26 Pd2(dba)3·CHCl3 (18 mg, 0.017 
mmol, 7.5 mol%) and SPhos (15 mg, 0.035 mmol, 15 mol%) were added 
to a sealed vial and vacuum dried for 1 h. They were dissolved in 1.1 mL 
of n-butanol and allowed to stir at room temperature for 15 min. 4-DMAP-
N-oxide 11 (0.10 g, 0.23 mmol, 1.0 equiv.), anhydrous potassium 
phosphate (0.15 mg, 0.70 mmol, 3.0 equiv.) and boronic ester 12 (0.17 g, 
0.47 mmol, 2.0 equiv.) were added to a separate sealed vial and vacuum dried for 1 h before 
the addition of the catalyst solution. The brown mixture was then allowed to stir for 8 h at 90 °C. 
The resulting solution was concentrated in vacuo and purified by column chromatography (0-
20% 2-propanol in EtOAc) to provide a yellow solid (0.10 g, 79 %). m.p. = 67.9 – 70.2 °C (dec.); 
Rf  = 0.40 (10% 2-propanol in EtOAc); IR (neat, cm-1) 2932, 1635, 1378, 1270, 1132; 1H NMR 
(400 MHz, CDCl3):  8.13 – 7.94 (m, 3H), 7.81 – 7.71 (m, 3H), 7.66 – 7.60 (m, 4H), 7.50 – 7.44 
(m, 4H), 7.42-7.36 (m, 2H), 6.40 (dd, J = 7.5, 3.5 Hz, 1H), 6.27 (d, J = 3.5, 1H), 2.88 (s, 6H); 
13C NMR (100 MHz, CDCl3):   145.1, 141.6, 140.2, 139.2, 130.5, 128.9, 127.7, 127.1, 126.2, 
125.6, 109.6, 108.4, 39.7; LRMS (m/z +ES): Found: M+H, 579.2. C33H25F6N2O+ requires M+H, 
579.2. Spectroscopic data in agreement with literature.26 
 
5'-Chloro-1,1':3',1''-terphenyl (14)73 
 According to the method of Kang,34 after dissolving 1,3-dibromo-5-
dichlorobenzene (0.15 g, 0.56 mmol, 1 equiv.), phenyl boronic acid (0.16 mg, 
1.3 mmol, 2.4 equiv.) and  Pd(PPh3)4 (45 mg, 0.039 mmol, 7 mol %) in a mixture 
solvent of 2M K3PO4 aqueous solution,  toluene and 1,4-dioxane (1:4:1, 4.5 mL) the mixture was 
stirred under reflux at 120 °C for 5 hours. The resulting mixture was then diluted with 5 mL of 
EtOAc, the aqueous phase extracted with EtOAc and dried over MgSO4. The residue was 
concentrated in vacuo and purified by column chromatography (petroleum ether) to provide a 
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white solid (78 mg, 53%). m.p. = 90.1 – 92.3 °C; Rf  = 0.35 (petroleum ether); IR (neat, cm-1) 
3035, 1685, 1596, 1566, 754; 1H NMR (400 MHz, CDCl3):  7.69 (t, J = 1.6 Hz, 1H), 7.66 – 7.62 
(m, 4H), 7.58 (d, J = 1.6 Hz, 2H), 7.52 – 7.46 (m, 4H), 7.45 – 7.39 (m, 2H); 13C NMR (100 MHz, 
CDCl3):   143.6, 140.0, 135.2, 129.1, 128.1, 127.4, 126.2, 124.5; HRMS (m/z +EI): Found: M+, 
264.0701. C18H1335Cl+ requires M+, 264.0706; ∆ = -0.5 ppm. Spectroscopic data in agreement 
with literature.73 
 
2-([1,1':3',1''-Terphenyl-5')-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (12)74 
According to the method of Kang,34 Pd2(dba)3·CHCl3 (97 mg, 0.093 mmol, 5 
mol%) and SPhos (0.15 mg, 0.37 mmol, 20 mol%) were added to a sealed vial 
and vacuum dried for 1 h. They were dissolved in 3.0 mL of anhydrous 1,4-
dioxane and allowed to stir at room temperature for 15 min. Terphenyl 14 (0.50 g, 
1.9 mmol, 1.0 equiv.), potassium acetate (1.1 g, 11 mmol, 6.0 equiv.) and bis(pinacolato)diboron 
(1.4 g, 5.7 mmol , 3.0 equiv.) were added to a separate sealed vial and vacuum dried for 1 h, 
before the addition of 20 mL of anhydrous 1,4-dioxane and the catalyst solution. The resulting 
red solution was then allowed to stir at 120 °C for 2 h. After this time, the reaction mixture was 
poured into 20 mL of water, extracted with CH2Cl2 (3 x 5 mL), dried over MgSO4 and 
concentrated in vacuo. The resulting oil was purified by column chromatography (petroleum 
ether/EtOAc, 10:1) to provide the product as a pale yellow solid (0.67 g, 98%). Rf = 0.80 
(petroleum ether/EtOAc, 4:1); IR (neat, cm-1) 2973, 1589, 1463, 1371, 1140; 1H NMR (400 MHz, 
CDCl3):  8.03 (d, J = 1.9 Hz, 2H), 7.91 (t, J = 1.9 Hz, 1H), 7.71 – 7.66 (m, 4H), 7.49 – 7.42 
(m, 4H), 7.39 – 7.33 (m, 2H), 1.38 (s, 12H); 13C NMR (100 MHz, CDCl3):   141.3, 141.3, 132.7, 
129.1, 128.8, 127.5, 127.5, 25.1;  LRMS (m/z +EI): Found: M+H, 357. C24H26BO2+ requires 
M+H, 357. Spectroscopic data in agreement with literature.74 
 
1,1':3',1''-Terphenyl-5'-boronic acid (15) 
Based on the procedure of Hartwig,75 boronic ester 12 (50 mg, 0.14 mmol, 1.0 
equiv.) and sodium periodate (89 mg, 0.42 mmol, 3.0 equiv.) were dissolved in a 
water/THF mixture (5:4, 0.27 mL) and allowed to stir for 15 min. Then, 0.30 mL of 
aqueous solution of hydrochloric acid (1M) were added, and the mixture was stirred for 4 h at 
room temperature. The resulting solution was extracted with EtOAc (3 x 2 mL), washed with 
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water (2 mL) and brine (2 x 2 mL), dried over MgSO4 and concentrated in vacuo to provide a 
white solid (31 mg, 81 %). m.p. = 288-290 °C; IR (film, cm-1): 3034, 1419, 1363, 1261, 887; 
1H  NMR (400 MHz, DMSO-d6): 8.26 (s, 2H), 8.08 (d, J = 1.9 Hz, 2H), 7.92 (t, J = 1.9 Hz, 1H), 
7.77 (d, J = 7.6 Hz, 4H), 7.50 (t, J = 7.6 Hz, 4H), 7.39 (t, J = 7.6 Hz, 2H). 13C NMR (100 MHz, 
DMSO-d6):  141.0, 140.4, 132.2, 129.4, 127.9, 127.4, 127.2; LRMS (m/z -ES): Found: M-
H+HCO2H adduct, 319.1. C19H18BO4- requires M-H+HCO2H adduct, 319.1 
 
6.3. PREPARATION OF THE PHOSPHORYLATING REAGENT 23 
2-N,N-Diisopropylamino-1,3,2-dithiaphospholane (20)30 
According to the method of Okruszek,30 into a solution of freshly distilled 
phosphorus trichloride (1 mL, 11.5 mmol, 1.0 equiv.) in anhydrous toluene/benzene 
(1:1, 10 mL), a solution of freshly distilled diisopropylamine (3.2 mL, 23 mmol, 
2.0 equiv.) in 2.0 mL of toluene was added dropwise with vigorous stirring and cooling to 0 °C. 
The resulting suspension was then allowed to stir for 1 h at room temperature, filtered through a 
cannula under nitrogen, and the precipitate thoroughly washed with toluene/hexane (1:1, 
15 mL). The combined fractions were cooled to 0 °C and a solution of 1,2-ethanedithiol (1,1 mL, 
13 mmol, 1.1 equiv.) and freshly distilled triethylamine (3.2 mL, 23 mmol, 2 equiv.) in 6.0 mL of 
dry toluene was added dropwise with vigorous stirring. The resulting mixture was then stirred for 
1 h, filtered through a cannula under nitrogen and the precipitate thoroughly washed with 
toluene/hexane (1:1, 20 mL). The combined fractions were concentrated in vacuo to yield the 
product as a colourless oil (1.7 g, 64 %) with no need for further purification. 1H NMR (400 MHz, 
CDCl3):  3.52 – 3.44 (m, 4H), 3.15 – 3.09 (m, 2H), 1.17 (d, J = 6.8 Hz, 12H); 31P NMR 
(162 MHz, CDCl3):  94.64. Spectroscopic data in agreement with literature.30 
 
5’-O-Trityl-thymidine (21)76 
According to the method of Takeshi,77 trityl chloride (0.30 g, 1.1 mmol,  
1.3 equiv.) was added to a solution of thymidine (0.20 mg, 0.83 mmol, 
1 equiv.) in pyridine (2.0 mL) and allowed to stir at 70 °C for 18 h. The 
reaction mixture was then quenched with saturated NaHCO3 solution 
(2.0 mL). The phases were separated and the aqueous layer extracted with CH2Cl2 (3 x 5 mL). 
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The combined organic layers were washed with brine, dried over MgSO4 and concentrated in 
vacuo. The resulting oil was purified by column chromatography (0-3% MeOH in CH2Cl2) 
providing the product as a white solid (0.16 g, 43%). Rf = 0.30 (5% MeOH in CHCl3); 1H NMR 
(400 MHz, CDCl3):  7.95 (s, 1H), 7.54 (s, 1H) , 7.46 – 7.28 (m, 15H), 6.39 (t, J = 6.8 Hz, 1H), 
4.58 (br s, 1H), 4.03 (q, J = 3.1 Hz, 1H), 3.49 (dd, J= 10.5, 3.3 Hz, 1H), 3.39 (dd, J = 10.5, 
3.1  Hz, 1H),  2.48 – 2.26 (m, 2H), 1.50 (s, 3H); LRMS (m/z -ES): Found: M-H, 483.2. 
C29H27N2O5- requires M-H, 483.2. Spectroscopic data in agreement with literature.76 
 
5’-O-Tritylthymidine-3’-O-(1,3,2-dithiaphospholane) (22)29  
According to the method of Okruszek,30 5’-O-trityl-thymidine (0.10 g, 
0.21 mmol, 1.0 equiv.) and a tetrazole solution in acetonitrile (0.46 mL, 
0.45 M, 0.21 mmol, 1.0 equiv.) were added to a sealed vial and vacuum dried 
for 8 h. Then, a solution of dithiaphospholane 20 (69 mg, 0.31 mmol, 1.5 
equiv.) in CH2Cl2 (2 mL) was added dropwise, and the reaction mixture was 
allowed to stir for 16 h at room temperature. The resulting solution was purified by column 
chromatography (0-5 % MeOH in CHCl3) to provide a white solid (0.11 g, 86 %). Rf = 0.55 
(5% MeOH in CHCl3); 1H NMR (400 MHz, CDCl3):  8.15 (s, 1H), 7.57 (d, J = 1.3 Hz, 1H), 7.42 
– 7.27 (m, 15H), 6.33 (dd, J = 8.2, 5.7 Hz, 1H), 4.72 – 4.66 (m, 1H), 4.09 (m, 1H), 3.51 (dd, 
J = 10.7, 2.6 Hz, 1H), 3.36 (dd, J = 10.6, 2.6 Hz, 1H), 3.32 – 3.10 (m, 4H), 2.49 (ddd, J = 13.4, 
5.7, 2.3 Hz, 1H), 2.37 – 2.28 (m, 1H), 1.43 (d, J = 1.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
 163.5, 150.1, 143.3, 135.5, 128.8, 128.2, 127.7, 111.5, 85.3, 84.7, 63.0, 41.9, 40.0, 11.9; 
31P NMR (162 MHz, CDCl3):  152.92; LRMS (m/z -ES): Found: M-H, 605.2. C31H30N2O5PS2- 
requires M-H, 605.1. Spectroscopic data in agreement with literature.29 
 
5’-O-Tritylthymidine-3’-O-(2-oxo-1,3,2-dithiaphospholane) (23)30 
According to the method of Okruszek,30 dithiaphospholane 22 (0.10 g, 0.17 
mmol, 1.0 equiv.) was dissolved in anhydrous toluene (1.0 mL) before the 
addition of 5–6 M decane solution of tert-butyl hydroperoxide (40 μL, 0.18 
mmol, 1.1 equiv.). The resulting solution was allowed to stir for 1 h under a 
nitrogen atmosphere at room temperature. The solution was then quenched 
by the addition of hexane at 0 °C, which caused the product to precipitate as a white solid. The 
40 Hernández Lladó, Pol 
 
suspension was then centrifuged and the solid cleaned with cold hexane (92 mg, 90 %). Rf = 
0.50 (5% MeOH in CHCl3); 1H NMR (400 MHz, CDCl3) for both conformers:   8.38 (s, 1H), 7.57 
(d, J = 1.4 Hz, 1H), 7.41 – 7.27 (m, 15H), 6.48 (dd, J = 8.6, 5.5 Hz, 1H, major conformer), 6.22 
(dd, J = 7.7, 6.3 Hz, 1H, minor conformer), 5.37 – 5.31 (m, 1H), 4.35 – 4.30 (m, 1H), 3.71 – 3.35 
(m, 4H), 2.71 (ddd, J = 14.2, 5.5, 1.9 Hz, 1H), 1.92 (m, 1H), 1.41 (d, J = 1.4 Hz, 3H); 31P NMR 
(162 MHz, CDCl3):  82.74 (minor conformer), 81.66 (major conformer); LRMS (m/z +ES): 
Found: M+NH4, 640.2. C31H35N3O6PS2+ requires M+NH4, 640.2. Spectroscopic data in 
agreement with literature.30. 
Note: 5’-O-tritylthymidine-3’-O-(2-oxo-1,3,2-dithiaphospholane) exists as a mixture of two 
conformers (syn and anti). Their relative populations vary with temperature and solvent.  
 
6.4. PREPARATION OF THE BIFUNCTIONAL CATALYSTS  
1-[(1R,2R)-2-Aminocyclohexyl]-3-[3,5-bis(trifluoromethyl)phenyl]thiourea ((R,R)-C1)69 
According to the method of Berkessel,69 phenyl chlorothioformate 
(0.12 mL, 0.88 mmol, 1.0 equiv.) was added to a solution of 3,5-
bis(trifluoromethyl)aniline (0.14 mL, 0.88 mmol, 1.0 equiv.) and pyridine 
(78 μL, 0.96 mmol, 1.1 equiv.) in CH2Cl2 (3.0 mL) at room temperature. 
The resulting yellow solution was stirred for 2 h, then added dropwise to a solution of (1R,2R)-
1,2-diaminocyclohexane (0.10 mg, 0.88 mmol, 1.0 equiv.) in CH2Cl2 (0.50 mL), followed by the 
addition of N,N-diisopropylethylamine (0.15 mL, 0.88 mmol, 1.0 equiv.). Then, the mixture was 
allowed to stir at room temperature for 15 min, and quenched with a saturated NaHCO3 
solution (3.0 mL). The phases were separated, and the aqueous layer extracted with 
CH2Cl2 (3 x 5mL). The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated in vacuo. The resulting oil was purified by column chromatography (CHCl3/MeOH, 
7:1) to obtain a pale yellow solid (0.14 g, 42%). Rf = 0.10 (MeOH/CHCl3/NEt3, 3:17:1); 1H NMR 
(400 MHz, DMSO-d6): 8.31 (s, 2H), 7.74 (s, 1H), 4.28 (br s, 1H), 3.01 (s, 1H), 2.04-1.93 
(m, 2H), 1.70 (br s, 2H), 1.25 (br s, 4H); []D23 +75.2 (c 0.93, CHCl3); LRMS (m/z +ES): Found: 
M+H, 386.1. C15H18F6N3S+ requires M+H, 386.1. Spectroscopic data in agreement with 
literature.69 
Note: (S,S)-C1 was prepared following the same procedure. 
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1-[3,5-Bis(trifluoromethyl)phenyl]-3-[(1R,2R)-2-(dimethylamino)cyclohexyl]thiourea ((R,R)-
C2)49 
According to the method of Berkessel,69 zinc powder (17 mg, 0.26 
mmol, 4.0 equiv.), acetic acid (30 μL, 0.52 mmol, 8.0 equiv.) and 
aqueous formaldehyde (37%, 23 μL, 3.0 equiv.) were added to a 
solution of (R,R)-C1 (25 mg, 0.065 mmol, 1.0 equiv.) in 1,4-dioxane 
(0.15 mL). The resulting suspension was then allowed to stir for 72 h at room temperature. 
Aqueous NH3 (80 μL) was added, the aqueous layer extracted with CH2Cl2 (3 x 1 mL) and the 
combined organic layers dried over MgSO4. The solvent was removed in vacuo and the residue 
purified by column chromatography (CHCl3/MeOH, 7:1) to obtain an off-white solid (15 mg, 
56 %). Rf = 0.15 (MeOH/CHCl3/NEt3, 3:17:1);  1H NMR (400 MHz, CDCl3): 7.83 (s, 2H), 7.62 
(s, 1H), 6.20 (br s, 1H), 3.77 (br s, 1H), 3.28 (br s, 1H), 2.74 (s, 6H), 2.44 – 2.41 (m, 1H), 1.91 – 
1.78 (m, 4H), 1.33 – 1.16 (m, 4H). []D23 -28.3 (c 1.0, CHCl3); LRMS (m/z +ES): Found: M+H, 
414.1. C17H22F6N3S+ requires M+H, 414.1. Spectroscopic data in agreement with literature.49 
Note: (S,S)-C2 was prepared following the same procedure. 
 
1-(3,5-Bis(trifluoromethyl)phenyl)-3-((1R,2R)-2-(isopropylamino)cyclohexyl) thiourea 
((R,R)-C3)78 
According to the method of Todd,78 acetone (9.0 μL, 0.10 mmol, 1.2 
equiv.) and NaBH(OAc)3 (40 mg, 0.19 mmol, 1.9 equiv.) were added 
to a solution of (R,R)-C1 (40 mg, 0.10 mmol, 1.0 equiv.) in 1,2-
dichloroethane (1.6 mL). The resulting mixture was stirred at room 
temperature for 16 h. Then, 6.0 mL of saturated NaHCO3 solution were added to the reaction 
mixture, which was then allowed to stir for 15 min. Layers were separated and the aqueous 
phase extracted with CH2Cl2 (3 x 10 mL). The combined organic phases were dried over 
MgSO4, concentrated in vacuo and purified by column chromatography (5% MeOH in CH2Cl2) to 
provide an off-white solid (22 mg, 50%). Rf = 0.20 (MeOH/CHCl3/NEt3, 3:17:1); 1H NMR 
(400 MHz, CDCl3):  8.15 (s, 2H), 7.57 (s, 1H), 6.58 (br s, 1H), 3.40 (br s, 1H), 3.00 (br s, 1H), 
2.38 (br s, 1H), 2.06 – 2.01 (m, 2H), 1.77 (br s, 2H), 1.40 – 1.19 (m, 4H), 1.17 (d, J = 6.3 Hz,  
3H), 1.11 (d, J = 6.0 Hz, 3H); []D23 +95.3 (c 0.83, CHCl3); LRMS (m/z -ES): Found: M-H, 426.1. 
C18H22F6N3S- requires M-H, 426.1. Spectroscopic data in agreement with literature.78 
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6.5. GENERAL PROCEDURE FOR THE SYNTHESIS OF DINUCLEOSIDE 
PHOSPHOROTHIOATES 40.A-C FROM DITHIAPHOSPHOLANE 23  
Dithiaphospholane 23 (5 mg, 0.008 mmol, 1.0 equiv.), 3-O-acetyl-2-deoxyribonucleoside 
39.a-c (0.008 mmol, 1.0 equiv.), catalyst (25 mol%) and 4 Å molecular sieves (10 mg) were 
added to a sealed vial and vacuum dried for 8 h. Then, 0.10 mL of anhydrous CH2Cl2 was 
added to the mixture and the resulting suspension allowed to stir for 15 min at room 
temperature under an argon atmosphere. This was followed by the addition of 0.20 mL of PMP 
solution in CH2Cl2 (0.008 mmol, 1.0 equiv.). After 16 h at room temperature under an argon 
atmosphere, the mixture was filtered through celite and analysed by 31P NMR.  
 
SP-(5’-O-Tritylthymidylyl)-3',5'-(3’-O-acetylthymidine) phosphoromonothiolate 1,2,2,6,6-
pentamethylpiperidinium salt (40.a)30 
31P NMR (162 MHz, CHCl3):  54.22 (RP) , 53.57 (SP)  
HRMS (m/z -ES): Found: M-PMPH-, 845.2261. 
C41H42N4O12PS- requires M-PMPH-, 845.2258; 
∆ = 0.3 ppm. Spectroscopic data in agreement with 
literature.30 
 
 
SP-(5’-O-Tritylthymidylyl)-3',5'-(3’-O-acetyl-2’-deoxyadenosine) phosphoromonothiolate 
1,2,2,6,6-pentamethylpiperidinium salt (40.b)30 
31P NMR (162 MHz, CHCl3):  54.27 (RP), 53.70 (SP).  
HRMS (m/z -ES): Found: M-PMPH-, 854.2401. 
C41H41N7O10PS- requires M-PMPH-, 854.2379; 
∆ = 2.6 ppm. Spectroscopic data in agreement with 
literature.30 
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SP-(5’-O-Tritylthymidylyl)-3',5'-(N4-acetyl-3’-O-acetyl-2’-deoxycytidine) phosphoromono-
thiolate 1,2,2,6,6-pentamethylpiperidinium salt (40.c)30 
31P NMR (162 MHz, CHCl3):  54.24 (RP), 53.69 (SP). 
HRMS (m/z -ES): Found: M-PMPH-, 872.2359. 
C42H43N5O12PS- requires M-PMPH-, .872.2367; 
∆ = 0.9 ppm. Spectroscopic data in agreement with 
literature.30 
 
 
 
6.6. GENERAL PROCEDURE FOR THE MEASUREMENT OF THE NATURAL SELECTIVITY IN 
THE SYNTHESIS OF DINUCLEOSIDE PHOSPHOROTHIOATES 40.A-C FROM 
DITHIAPHOSPHOLANE 23 
Dithiaphospholane 23 (5 mg, 0.008 mmol, 1.0 equiv.) and 3-O-acetyl-2-deoxyribonucleoside 
39.a-c (0.008 mmol, 1.0 equiv) were added to a sealed vial and vacuum dried for 8 h. Then, a 
solution of the base of choice (0.008 mmol, 1.0 equiv.) in CH2Cl2 (0.1mL) was added to the vial 
and the resulting solution allowed to stir at room temperature for 16 h under an argon 
atmosphere.  The reaction mixture was analysed by 31P NMR.   
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7. CONCLUSIONS 
In summary, the present study has found promising results which point towards the first 
asymmetric catalytic synthesis of dinucleoside phosphorothioates. Even though high levels of 
selectivity and conversion have not been achieved, it has been proved that these catalysts do 
affect the selectivity of the reaction. Further work is needed in order to find better catalysts and 
conditions for the coupling. 
Moreover, an interesting base dependence on the diastereoselectivity of the coupling 
reaction has been found. The reasons for this switch in diastereoselectivity are not currently 
known; however, computational and Sigman analysis may shed some light on the subject 
through the study of its transition state. 
Optimisation of the coupling conditions in the presence of the 4-DMAP-N-oxide catalyst 3 
was not achieved, since an adequate additive was not found. However, an improvement in the 
synthesis of this catalyst was developed, enabling its preparation in 43% overall yield over 
5 steps.   
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9. ACRONYMS 
4Å MS 4 angstrom molecular sieves 
4-DMAP 4-dimethylaminopyridine 
AcOH acetic acid 
dAde 2’-O-deoxyadenosine 
DBU 1,8-diazabicyclo(5.4.0)undec-7-ene 
dCyt 2’-O-deoxycytidine 
DIPEA N,N-diisopropylethylamine 
DNA deoxyribonucleic acid 
EI electron ionization 
ES electrospray ionization 
FDA Food and Drug Administration 
HPLC  high-performance liquid chromatography 
HRMS high-resolution mass spectrometry 
IR infrared spectroscopy 
LRMS low-resolution mass spectrometry 
m.p. melting point 
m-CPBA meta-chloroperoxybenzoic acid 
mRNA messenger RNA 
MS mass spectrometry 
na not available 
NBS N-bromosuccinimide 
nr no reaction 
ON oligonucleotide 
50 Hernández Lladó, Pol 
 
PBH3-ON boranophosphate oligonucleotides 
PMe-ON methylphosphonate oligonucleotide 
PMP 1,2,2,6,6-pentamethylpiperidine 
PPO propylene oxide 
PSe-ON phosphoroselenoate oligonucleotide 
PS-ON phosphorothioate oligonucleotide 
pyr pyridine 
Rf retention factor 
RNA ribonucleic acid 
RP-HPLC reverse-phase high-performance liquid chromatography 
SPhos 2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl 
THF tetrahydrofuran 
Thy thymidine 
TLC thin-layer chromatography 
TMP 2,2,6,6-tetramethylpiperidine 
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APPENDICES 
 APPENDIX: SCREENING OF CONDITIONS FOR THE 
COUPLING BETWEEN DITHIAPHOSPHOLANE 23 AND 
THYMIDINE 39.A 
 
Entry T (°C) t  (h) c (mol/L) Base (n equiv.) Catalyst (m mol%) Conv. (%)a 
1 -78 2 0.05 PMP (1 equiv.) 6 (20%) 25 
2 -78 2 0.05 PMP (1 equiv.) 6 (20%)+ 30 (1%) 45 
3 rt 0.5 0.05 DBU (1 equiv.) - 100 
4 -78 1 0.04 PMP (1 equiv.) 30 (10 mol%) nr 
5 0 1.5 0.04 PMP (1 equiv.) 30 (10 mol%) nr 
6 rt 1 0.04 PMP (1 equiv.) 30 (10 mol%) nr 
7 -78 1 0.04 PPO (1 equiv.) 30 (10 mol%) nr 
8 0 1.5 0.04 PPO (1 equiv.) 30 (10 mol%) nr 
9 rt 1 0.04 PPO (1 equiv.) 30 (10 mol%) nr 
10 -78 2 0.05 PMP (1 equiv.) (±)-C1 (25 mol%) nr 
11 0 3 0.05 PMP (1 equiv.) (±)-C1 (25 mol%) 24 
12 -78 2 0.05 PMP (1 equiv.) (±)-C2 (25 mol%) nr 
13 0 3 0.05 PMP (1 equiv.) (±)-C1 (25 mol%) 19 
14 0 3 0.15 PMP (3 equiv.) - 25 
15 0 3 0.15 PMP (3 equiv.) (±)-C1 (25 mol%) 25 
16 0 3 0.15 PMP (1 equiv.) - 25 
17 0 3 0.15 PMP (1 equiv.) (±)-C1 (25 mol%) 25 
18 0 2 0.05 PMP (1 equiv.) - 20 
19 0 2 0.05 PMP (1 equiv.) (±)-C1 (25 mol%) 50 
20 -20 2.5 0.05 TMP (1 equiv.) - 20 
21 -20 2.5 0.05 TMP (1 equiv.) (±)-C1 (25 mol%) 30 
22 rt 4 0.01 PMP (1 equiv.) - nr 
23 rt 4 0.01 PMP (1 equiv.) (±)-C1 (25 mol%) 15 
24b rt 16 0.03 PMP (1 equiv.) - nr 
25b rt 16 0.03 PMP (1 equiv.) (±)-C1 (25 mol%) 25 
(a) Determined by 31P NMR; (b) Reaction carried out with 10mg 4Å MS 
 
